E-Cigarette Statistics Show Why Cannabis Stocks Are Just Getting Started

Recent data suggests that cannabis growth is just getting started. Stocks like Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Cronos Group (TSX:CRON)(NASDAQ:CRON) remain your best bets.

| More on:
edit Jars of marijuana

Image source: Getty Images

E-cigarettes are currently roiled in controversy, albeit sales growth remains positive. Looking back, it’s amazing how quickly this industry emerged.

In 2013, the global vaping market was worth just $4 billion. This year, it’s expected to approach $20 billion, which represents 500% growth in just six years.

By 2023, Euromonitor International expects the market size to surpass $45 billion. Given that the traditional cigarette market is worth around $1 trillion worldwide, decades of growth could be ahead for e-cigarettes.

Few markets are capable of this type of momentum, yet the cannabis industry looks the part. In fact, despite the hype around legalized marijuana, the data suggests that the growth has just begun.

Just getting started

The e-cigarette market shows just how quickly these markets can form and accelerate. The traditional tobacco market shows how large these markets can become over time, yet there are many cannabis-specific data points that also suggest a positive future.

In 2018, the U.S. market generated $8 billion in legal cannabis sales. Over the next several years, Cowen Inc believes that the market will grow by 30% annually, surpassing $30 billion by 2025. Several other investment banks and research firms have corroborated this projection.

Canada is expected to experience similar growth, although the country’s sales ramp is a bit ahead of its southern neighbour.

In February of this year, for example, Canadians purchased $49 million in legal pot. By June, sales had reached $85 million.

Given that the sale of popular form factors like edibles and concentrates weren’t legalized until this October, expect monthly sales to pick up considerably as 2019 comes to a close.

It’s not just industry-wide sales that are projected to rise, however. Revenue for nearly every pot stock is expected to ramp in 2020 as the market matures and consumer preferences are better aligned.

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is expected to generate US$310 million in sales this year.

Next year, however, sales are expected to more than double to US$706 million. Some analysts believe sales will grow by more than 40% annually over the next five years.

Its tie-up with Constellation Brands will surely help it capitalize on the burgeoning consumables category.

Cronos Group (TSX:CRON)(NASDAQ:CRON) is another cannabis company set for rapid growth. Analysts expect just US$38 million in revenue this year.

By the end of next year, that figure should grow to US$133 million. Tobacco behemoth Altria Group Inc, which controls half of U.S. cigarette sales, took a 45% position in the company this year.

If any stock is capable of becoming an industry giant, it’s Cronos Group, as it now has the expertise, funding, and influence of a firm with decades of success in highly-regulated markets.

The biggest sales gains, however, will be recorded by smaller competitors such as HEXO Corp. (TSX:HEXO)(NYSE:HEXO).

With a market cap of just $600 million, HEXO generated just US$36 million in sales this year. Next year, analysts expect sales to ramp to US$86 million.

By 2021, sales could approach US$200 million. With a differentiated platform approach to cannabis, this could be a long-term winner that few pot investors are paying attention to.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands, HEXO., and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »